On Wednesday, Pharmaceutical Giant Pfizer Agreed to Buy Baxter International’s Vaccines Unit Worth $635 Million
The deal will give Pfizer access to Baxter’s meningitis and encephalitis vaccine. Pfizer will also get access to part of a Baxter’s production facility in Austria, where the vaccines are made.
The deal is expected to be carried and closes by the end of the fiscal year. Despite this acquisition, Pfizer has said that it does not expect the deal to affect its full-year forecast. The company has, however, said that it expects this new deal to slightly dilute its fourth-quarter earnings, and lower its 2015 adjusted profit by 15 percent per share.
Both of the vaccines that Pfizer will acquire in the deal are available outside the US, in some European markets.